Loading stock data…
Nyxoah SA (NYXH)
$1.69+0.04 (+2.42%)
After Hours$1.66-0.03 (-1.78%)· Last close Jun 30
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nyxoah SA in the Healthcare sector is trading at $1.69 with a market capitalization of $154M. Wall Street consensus targets $8.33 (4 analysts), implying a +392.9% move over the next 12 months. The stock is currently near its 52-week low of $1.26, remaining 58.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 75 is overbought against a weak tape. The Whystock Score of 5/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +392.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 75 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.37M↑ | $5.64M↑ | $1.97M↑ | $1.34M↑ | $1.06M |
| Gross Profit | $3.64M↑ | $3.63M↑ | $1.19M↑ | $850,000↑ | $658,000 |
| Operating Income | -$20.50M↓ | -$18.26M↑ | -$24.20M↓ | -$19.85M↑ | -$20.64M |
| Net Income | -$15.94M↑ | -$23.51M↑ | -$23.58M↓ | -$20.61M↑ | -$22.38M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$153.89M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-233.18%
Volume
Today's trading volume
140,978
Recent News
Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Analyst Cuts And Capital Concerns
Nyxoah is under fresh scrutiny after analyst fair value estimates shifted from €9.0 to about €7.37 per share, an adjustment of roughly 18% that reflects a reset in price targets. Recent research links these cuts to more cautious assumptions around capital needs, valuation, and execution risk. At the same time, commentary still points to progress with the Genio launch and U.S. net revenue trends. As you read on, you will see how these changing targets, and the debate between bullish and...
Why Is NYXH Stock Falling Today?
The company priced its stock offering on Friday at a steep discount, with proceeds to be used to expand commercialization activities in the United States.
Nyxoah SA (NYXH) Q1 2026 Earnings Call Highlights: Strong U.S. ...
Nyxoah SA (NYXH) reports a 25% sequential U.S. revenue increase, while addressing production yield issues impacting gross margins.
Nyxoah Q1 Earnings Call Highlights
Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization. Chief Executive Officer Olivier Taelman said
Nyxoah SA (NYXH) Reports Q1 Loss, Tops Revenue Estimates
Nyxoah (NYXH) delivered earnings and revenue surprises of +19.88% and +4.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?